• Publications
  • Influence
Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
BACKGROUND Epidemiologic and animal studies have suggested that dietary fish or fish oil rich in omega-3 fatty acids, for example, docosahexaenoic acid and eicosapentaenoic acid, may preventExpand
  • 637
  • 33
  • PDF
Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms
Epidemiological and animal studies have suggested that dietary fish or fish oil rich in omega‐3 fatty acids (ω3), docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), may have effects inExpand
  • 171
  • 6
The Cerebrocortical Areas in Normal Brain Aging and in Alzheimer's Disease: Noticeable Differences in the Lipid Peroxidation Level and in Antioxidant Defense
The markers of oxidative stress were measured in four cerebrocortical regions of Alzheimer's disease (AD) and age-matched control brains. In controls the levels of diene conjugates (DC) and lipidExpand
  • 114
  • 6
Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer's disease patients
Evidence from epidemiological, clinical and experimental studies favour the hypothesis that inflammatory events are part of the neuropathology in Alzheimer's disease. Proinflammatory cytokines suchExpand
  • 80
  • 6
Effects of docosahexaenoic acid-rich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study.
BACKGROUND Dietary fish or fish oil rich in n-3 fatty acids (n-3 FAs), eg, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), ameliorate inflammatory reactions by various mechanisms. WhereasExpand
  • 154
  • 5
  • PDF
Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months
Objective To study the long-term dual inhibitory effects of rivastigmine on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) in patients with AD. MethodsEleven patients with mild ADExpand
  • 140
  • 4
- 3 Fatty Acid Treatment in 174 Patients With Mild to Moderate Alzheimer Disease : OmegAD Study A Randomized Double-blind Trial
Participants: Two hundred four patients with AD (age range [mean±SD], 74±9 years) whose conditions were stable while receiving acetylcholine esterase inhibitor treatment and who had a Mini-MentalExpand
  • 53
  • 3
Decreased inositol (1,4,5)-trisphosphate receptor levels in Alzheimer's disease cerebral cortex: selectivity of changes and possible correlation to pathological severity.
We used immunoblotting and radioligand binding techniques to compare levels of the calcium-mobilizing receptor for the phosphoinositide hydrolysis-derived intracellular second messenger inositolExpand
  • 57
  • 2
Docosahexaenoic acid stabilizes soluble amyloid‐β protofibrils and sustains amyloid‐β‐induced neurotoxicity in vitro
Enrichment of diet and culture media with the polyunsaturated fatty acid docosahexaenoic acid has been found to reduce the amyloid burden in mice and lower amyloid‐β (Aβ) levels in both mice andExpand
  • 43
  • 2
Regional distribution of somatostatin receptor binding and modulation of adenylyl cyclase activity in Alzheimer's disease brain
We have previously reported a reduction in the inhibitory effect of somatostatin on adenylyl cyclase activity in the superior temporal cortex of a group of Alzheimer's disease cases, compared to aExpand
  • 57
  • 1